All In Biotech

Drug Trial Radar · NCT06921837

A First-in-Human Study Using BDC-4182 as a Single Agent in Advanced Gastric and Gastroesophageal Cancer

A Phase 1/2, First-in-Human, Dose Escalation and Expansion Study of BDC-4182 as a Single Agent in Patients With Advanced Gastric and Gastroesophageal Cancer

Last checked: Nov 19, 2026Latest source record: Jan 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

122

Planned (sponsor's estimate)

Start

May 26, 2025

Primary completion

May 2027

Study completion May 2029

Sponsor

Lead sponsor
Bolt Biotherapeutics, Inc.Industry
Sponsor type
Industry
First posted
Apr 10, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A first-in-human study using BDC-4182 as a single agent in gastric and gastroesophageal cancers

Conditions

  • Gastric Cancer Adenocarcinoma Metastatic
  • Gastroesophageal Adenocarcinoma

Interventions

  • BDC-4182Drug

    Immune stimulating antibody conjugate (ISAC), consisting of an anti-claudin 18.2 monoclonal antibody conjugated to a TLR 7/8 dual agonist

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of adverse events (AEs) and serious adverse events (SAEs) graded according to CTCAE v5.0Time frame: approximately 2 years
  2. Incidence and nature of AEs considered by the Investigator or Sponsor to be clinically relevant, attributable to study treatment, and meeting dose-limiting toxicity (DLT) criteriaTime frame: Up to 21 days

Locations

16 sites in 3 countries. Site status is shown where the registry gives one.

  • AUS Site 2

    Darlinghurst, New South Wales, Australia · Recruiting

  • AUS Site 5

    Westmead, New South Wales, Australia · Recruiting

  • AUS Site 1

    Birtinya, Queensland, Australia · Recruiting

  • AUS Site 4

    Clayton, Victoria, Australia · Recruiting

  • AUS Site 3

    Heidelberg, Victoria, Australia · Recruiting

  • SK Site 2003

    Seongnam-si, South Korea · Recruiting

  • SK Site 2001

    Seoul, South Korea · Recruiting

  • SK Site 2002

    Seoul, South Korea · Recruiting

  • SK Site 2004

    Seoul, South Korea · Recruiting

  • SK Site 2005

    Seoul, South Korea · Recruiting

  • TWN Site 9004

    Kaohsiung City, Taiwan · Recruiting

  • TWN Site 9005

    Kaohsiung City, Taiwan · Recruiting

  • TWN Site 9001

    Taichung, Taiwan · Recruiting

  • TWN Site 9003

    Taipei, Taiwan · Recruiting

  • TWN Site 9006

    Taipei, Taiwan · Recruiting

  • TWN Site 9002

    Taoyuan, Taiwan · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.